American Heart Association

Stephen Nicholls, MBBS, PhD, provides additional insight into KRAKEN trial data and the potential of muvalaplin.

Marianna Fontana, MD, PhD discusses Phase 1 interim results on the CRISPR-based gene-editing therapy, nex-z, for ATTR-CM.

Stephen J. Nicholls, MD, PhD discusses the robust efficacy and tolerability of zerlasiran for Lp(a) lowering, paving the way for Phase 3 development.

Muthiah Vaduganathan, MD, MPH, discusses the need for cardiology to embrace a role for GLP-1 receptor agonists and incretin therapies, with a focus on obesity-related HFpEF.

Viet Le, PA-C, DMSc, breaks down new data and updates from AHA 24, spotlighting 3 specific trials and the applicability of artificial intelligence in care.

Muvalaplin, an oral treatment, reduced Lp(a) by up to 85% in a 12-week Phase 2 trial presented at AHA 2024.

Marianna Fontana, MD, PhD describes the prognostic importance of a decline in eGFR in a retrospective cohort of patients with ATTR-CM.

Zerlasiran reduced Lp(a) by over 90% at 60 weeks with consistent efficacy and no serious drug-related adverse events, supporting its phase 3 trial progression.

More than half of US adults—approximately 137 million—are candidates for semaglutide based on diabetes, weight management, or cardiovascular prevention indications.

A nasal spray form of bumetanide reduced tissue swelling from heart failure as effectively as the oral and intravenous formulations.

Sacubitril/valsartan reduced the risk of heart damage among high-risk cancer patients treated with anthracycline chemotherapy agents.

Christian. T. Ruff, MD, MPH describes an analysis of AZALEA-TIMI 71 demonstrating the substantial benefit of abelacimab on bleeding outcomes in patients on antiplatelet therapy.

Ankeet Bhatt, MD, MBA, ScM, provides additional insight into NUDGE-FLU data he presented at AHA 2024.

Electronic messages highlighting cardiovascular benefits of flu shots increased vaccination rates by 1.8% in heart attack survivors.

Barry A. Borlaug, MD describes the beneficial effect of tirzepatide on circulatory pressure-volume overload and end-organ damage in patients with HFpEF and obesity.

An IV infusion of exenatide during cardiac surgeries involving bypass did not significantly benefit mortality or organ injury compared with placebo.

Oussama Wazni, MD, discusses the results of the OPTION trial examining LAAC in atrial fibrillation as well as its reception as AHA 2024.

Obesity-related ischemic heart disease deaths rose from 1999 to 2020, particularly in middle-aged men and Black adults, per CDC WONDER data.

A single dose of nex-z achieved consistent and rapid reductions in serum TTR levels over 12 months of follow-up in patients with ATTR-CM.

Initial catheter ablation achieved a lower risk of a composite primary endpoint event than anti-arrhythmic drug therapy in patients who survived a heart attack.

Ankeet Bhatt, MD, MBA, discusses a study he led from AHA 2024 examining the cost-effectiveness of dapagliflozin based on how soon therapy was initiated following diagnosis or hospitalization.

Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with diabetes in the BPROAD trial.

Tirzepatide reduced the risk of heart failure hospitalization or cardiovascular death by 38% and improved body weight by up to 21% in the SUMMIT trial.

Once-daily aprocitentan is indicated to help lower blood pressure in adult patients with hypertension who are inadequately controlled on other medications.

Ahmad Masri, MD, MS, discusses new acoramidis data from the ATTRibute-CM trial at AHA 2023.

A post hoc analysis of the SCORED trial suggested the clinical benefit of sotagliflozin on heart failure and MACE-related outcomes in as early as 3 months in a high-risk population.

Presented at AHA 2023, new analyses of VOYAGER PAD suggest the benefit of rivaroxaban plus aspirin for high-risk and complex populations with PAD.

A group of 13 leading experts provides their perspectives on the top news in cardiovascular medicine from 2023, with responses ranging from novel approvals to new semaglutide data to gene therapy and more.

Christian Ruff, MD, MPH discusses results from the phase 2 AZALEA-TIMI 71 trial, the need for new antithrombotic therapies, and the net clinical benefit outcome of abelacimab for AF.

Viet Le, DMSc, PA-C, discusses early data from the Target-D trial and how this might influence the way he interprets the findings from other vitamin D supplementation studies.